QNRX (Quoin Pharmaceuticals) Future Price to Earnings

QNRX (quoinpharma.com) - company brandmark

Quoin Pharmaceuticals (QNRX) maintains an impeccable reputation in the therapy of rare dermatoses. The company's forward P/E ratio visualizes this status, where the 0.00 mark indicates the level of investment risk. The brand attracts leading biochemists with generous RSU packages. High profitability is driven by the global sale of patented formulas with minimal production costs.

Forward P/E Multiple: Quoin Pharmaceuticals (QNRX) for 07/04/2022 - 11/17/2026

quoinpharma.com (QNRX) - metric breakdowns and financial figures

Initial company analysis:Quoin Pharmaceuticals Ltd QNRX
Signature product of Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) focuses on therapies for ultra-rare dermatological diseases, which, combined with regular equity dilution, complicates profit forecasting. The forward P/E ratio relates the current share price to the expected net income for the following year; therefore, fluctuations in the company's projected P/E reflect the market's reassessment of risks associated with prolonged clinical trials and the volatility of the business's fundamental value.